![](https://etira.life/wp-content/uploads/2024/06/image-495x400.jpeg)
DECRYPTING THE OLIGO-BENZAMIDE PLATFORM
NewsDallas, TX – June 15, 2024 – The laboratory of Etira founder Dr Jung-Mo Ahn presents a comprehensive overview of the oligo-benzamide platform that emulates a-helical peptide segments in proteins and disrupts protein-protein interactions.…
![](https://etira.life/wp-content/uploads/2024/05/Etira-Image-for-Press-Release-495x400.jpg)
ERX-315 SUBMITTED FOR HREC APPROVAL
NewsDallas, TX – May 14th, 2024 - Etira is pleased to announce the submission of the regulatorydocuments for approval of administration of its breakthrough oncology drug ERX-315 to theHuman Research Ethics Committee (HREC) in Australia.…
![](https://etira.life/wp-content/uploads/2024/05/Unknown-495x400.jpeg)
ERX-208 potency in Ovarian Cancer
NewsSan Diego, CA. April 10, 2024: Etira founder Dr Ratna Vadlamudi’s laboratory presents comprehensive data on the activity of ERX-208 in ovarian cancer. ERX-208 is active against all four molecular subtypes of ovarian cancer and its activity…
![](https://etira.life/wp-content/uploads/2024/01/image-495x400.png)
Targeting LIPA in ovarian cancer
NewsDallas, TX. January 24, 2024: We are pleased to present a manuscript in Cancers from the laboratory of Etira founder Dr. Ratna Vadlamudi. The data presented show that ERX-41 targets LIPA in ovarian cancer and is effective against all 4 subtypes…
![](https://etira.life/wp-content/uploads/2024/02/image-1-495x400.jpeg)
ERX-315 introduced at SABCS 2023
NewsSan Antonio, TX. December 7, 2023: Etira is pleased to present the data with its lead compound ERX-315 that cause catastrophic levels of ER stress, resulting in breast cancer cell death, and that can successfully function against multiple forms…
![](https://etira.life/wp-content/uploads/2023/10/image-495x400.png)
Independent validation of LIPA as a molecular target in TNBC
NewsDallas, TX. October 2, 2023: Etira is pleased to note the independent validation of LIPA as a molecular target in TNBC in a preprint in biorxiv from Dr. Esser’s group in Dusseldorf, Germany.
The authors conclude that LIPA-activity is a novel…
![](https://etira.life/wp-content/uploads/2023/06/nature-cancer-thumbnail-495x400.jpg)
One year later, highest almetric score for any paper published in Nature Cancer!
News Dallas, Texas. June 1, 2023:
One year after its online publication, we are pleased to note that our manuscript titled “Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid…
![](https://etira.life/wp-content/uploads/2023/04/Annual-Meet-Feature-Image-495x400.jpg)
Positive preclinical data presented at AACR 2023
News Dallas, Texas. April 18, 2023:
Etira is pleased to announce that multiple abstracts related to their licensed products showed encouraging preclinical activity in metastatic breast cancer and ovarian cancer. The data, presented…
![](https://etira.life/wp-content/uploads/2023/04/UT-Health-Feature-Health-495x400.jpg)
Etira founder Dr. Ratna Vadlamudi honored with the prestigious 2023 Distinguished Research Scholar Award
NewsDallas, Texas. April 17, 2023:We are excited to congratulate one of our founders, Dr. Ratna Vadlamudi, Professor and Vice Chair for Research, Division of Reproductive Research, Department of Obstetrics & Gynecology, Long School of…
![](https://etira.life/wp-content/uploads/2022/12/San-Antonio-Breast-Cancer-Thumbnail-1-495x400.jpg)
Preclinical data on TNBC presented at SABCS 2022
NewsDallas, Texas. December 9, 2022:
Etira is pleased to report the abstract related to ERX-41 validating its activity in Triple negative breast cancer was presented at the San Antonio Breast Cancer Symposium (SABCS). The SABCS is one of the world's…